U.S. Medical Marijuana Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

On account of medicinal properties and widespread applications in therapeutics, the rising demand of legalization will boost U.S. medical marijuana market expansion. Increased number of people suffering from severe pain caused by cancer, arthritis, HIV/AIDS, and neurological disorders will drive the market in the region. 

Reportedly, in the United States only 23 states allow citizen-initiated ballot initiatives, meaning in most states the only way to reform marijuana laws is via the legislature. With polls showing that 67% of Americans support making marijuana use legal and around 90% support allowing medical marijuana, lawmakers are increasingly getting the message that constituents want them to act on sensible and humane marijuana legalization in the U.S.

Request for a sample copy of this report @

Anorexia is an eating disorder and considered to be a potentially life-threatening disease that has been rapidly increasing in the U.S. Marijuana stimulates appetite which is vastly used in the treatment of anorexia. Reportedly, the U.S. medical cannabis industry share from anorexia segment is projected to experience significant growth of nearly 13.1% CAGR up to 2024.

There is a rising preference among the U.S. population to inhale medical cannabis on account of controlled dosage rate, better absorption into the body, and better perceiving rate with high peak concentrations. From the inhalation applications, U.S. medical marijuana industry is predicted to expand at 13.4% CAGR up to 2024.

The U.S. Pacific Central medical marijuana industry accounted for nearly US$2,085.9 million in 2017. The first state to legalize medical cannabis was California back in 1996. Similarly, other states in the U.S. such as Oregon, Washington, and Alaska got the approval for medicinal cannabis use in 1998.

The online distribution of marijuana in the U.S. is projected to grow considerably at a CAGR of 13.9% on account of hassle-free product movement. The growth of the online medical cannabis market is attributed to factors such as the convenience of product availability, vast product portfolio, and competitive costs. Also, the high market revenue of this segment is due to the effective customer service of the online distribution channel.

Leading companies in the U.S. medical marijuana industry include United Cannabis, Aurora Cannabis, Inc., Emerald Health Therapeutics, Medical Marijuana, Inc., Aphria, Inc., GW Pharmaceuticals, Tilray, and Canopy Growth. Increasing research and development activities, and strategic mergers and acquisition performed by these firms is factoring into the development of new and innovative medical cannabis products across the U.S.. 

Browse full table of contents (TOC) of this report @

Partial Chapter of the Table of Content 

Chapter 5.  U.S. Medical marijuana Market, By Route of Administration

5.1. U.S. medical marijuana market share, by route of administration, 2017 & 2024

5.2. Inhalation

5.2.1.  Market estimates and forecast, by region, 2013 – 2024

5.3. Oral

5.3.1.  Market estimates and forecast, by region, 2013 – 2024

5.4. Topical

5.4.1.  Market estimates and forecast, by region, 2013 – 2024

Chapter 6.  U.S. Medical marijuana Market, By Distribution Channel

6.1. Global medical marijuana market share, by distribution channel, 2017 & 2024

6.2. Dispensaries

6.2.1.  Market estimates and forecast, by region, 2013 – 2024

6.3. Online

6.3.1.  Market estimates and forecast, by region, 2013 – 2024


Leave a Reply